Q-omics provides the consensus-scored MYRFL profile across patient tissues and cancer cell-line models. MYRFL expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MYRFL is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MYRFL RNA expression shows 11,718 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where MYRFL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYRFL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYRFL survival associations across molecular data types. MYRFL RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYRFL RNA expression–survival associations across cancer types. High MYRFL expression shows unfavorable associations in MESO, ESCA, LGG and THCA, but favorable associations in KIRP and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MYRFL RNA expression.
This table summarizes MYRFL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MYRFL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYRFL shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, BRCA, BLCA and CHOL. The KIRC box plot shows higher MYRFL RNA expression in tumor versus normal tissue (log2 FC = +0.603, t-test p < 0.001).
This table shows molecular features associated with MYRFL in patient tissues and cancer cell lines. In patient samples, MYRFL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYRFL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
